Access to Medicine Index Gives Top Spots to GSK, J&J

Nov 20, 2016

The biennial Access to Medicine Index analyzes the top 20 research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries.

This year, Glaxosmithkline retains its top ranking, which it has held ever since the index was launched in 2008. GSK is followed by Johnson & Johnson in the 2 spot, then Novartis, Merck KGaA, Merck & Co, and Sanofi in that order.

The Access to Medicine Index uses a weighted analytical framework to consistently capture and compare data from the top 20 research-based pharmaceutical companies across a set of countries, diseases, and product types. The index is funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments.

See the full 2016 Index

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments